Bernardo Haddock Lobo Goulart
@lobo_goulart
Rough on the outside, a softie at the core; love my girls; data obsessive; Thoracic oncologist; outcomes researcher; @martialarts; @skiing. Views are own.
ID: 1237789786590474240
11-03-2020 17:19:17
258 Tweet
164 Followers
117 Following
Humbled for moderating a heated session on periop trial designs at AACR , with a great panel: Harpreet Singh, MD Raymond Osarogiagbon, MBBS, FACP Dr. Elizabeth Jaffee Michael Axelson Francesco Pignatti Manju George MVSc PhD Rectal Cancer Survivor Thank you all!
We need more smaller trials to evaluate the other checkpoints and understand whether they’re induced within and across cancer types. This is how we can understand when each combination should be used. Padmanee (Pam) Sharma, MD, PhD Jim Allison PhD AACR #AACR24
The Future of Registrational Trials with Multiple Arms: Bernardo Haddock Lobo Goulart will moderate this session at the FDA Oncology-AACR workshop on Trial Designs for Treatment Regimens with Multiple Phases (May 9). Learn more: bit.ly/3weWwmx #AACRSciencePolicy
Check out the state of immunotherapy in resectable NSCLC: This ASCO Ed Book article includes views from academia & FDA. Good warmup for #ASCO24 Education Session “Integrating Immunotherapy into Early-Stage Lung Cancer" on June 2. 🧵 1/2 ascopubs.org/doi/10.1200/ED… #OCEPublications
2/2 → Ongoing trials of immunotherapy and RT for early stage NSCLC. → Clinical implications of recent advances in immunotherapy for resectable NSCLC. → Current trial designs assessing immunotherapy in resectable NSCLC: challenges, opportunities. Bernardo Haddock Lobo Goulart #ASCO24
Look forward to discussing immunotherapy & trial designs for resectable NSCLC at #ASCO24 Ed session: Integrating Immunotherapy Into Early-Stage Lung Cancer. Join Rafal Dziadziuszko Jamie Chaft and Bernardo Haddock Lobo Goulart to review progress & challenges in this hot topic!
FDA Oncology Center's Dr. Luckson Mathieu will be speaking at Mass General Cancer Center 2024 #CancerEquityColloquium June 14-15. This hybrid event will address the diverse issues that underlie #cancerinequities. tinyurl.com/mryjj68b #OCETalks
Another option for patients with NSCLC and sensitizing EGFR mutations FDA Oncology Keep an eye on DVTs/PEs (36%) and don’t forget the recs for prophylactic anticoagulantion!